A Bmi1-miRNAs Cross-Talk Modulates Chemotherapy Response to 5-Fluorouracil in Breast Cancer Cells

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yin, Jiang ^a   Zheng, Guopei ^a   Jia, Xiaoting ^a   Zhang, Zhijie ^a   Zhang, Weijia ^a   Song, Ying ^a   Xiong, Yan ^a   He, Zhimin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CD24 ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 200C; MICRORNA 203; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BMI1 GENE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL STRAIN MDA MB 453; CELL SUBPOPULATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; EMBRYO; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WILD TYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 1;

EID: 84883645909     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073268     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Grayson M, (2012) Breast cancer. Nature 485: S49-S49. doi:10.1038/485S49a. PubMed: 22648496.
3. O'Driscoll L, Clynes M, (2006) Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets 6: 365-384. doi:10.2174/156800906777723958. PubMed: 16918307.
4. Ellis LM, Hicklin DJ, (2009) Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 15: 7471-7478. doi:10.1158/1078-0432.CCR-09-1070. PubMed: 20008847.
5. Sorrentino A, Liu C-G, Addario A, Peschle C, Scambia G, et al. (2008) Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111: 478-486. doi:10.1016/j.ygyno.2008.08.017. PubMed: 18823650.
6. Iwasa Y, Nowak MA, Michor F, (2006) Evolution of resistance during clonal expansion. Genetics 172: 2557-2566. PubMed: 16636113.
7. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, et al. (2011) Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71: 1858-1870. doi:10.1158/0008-5472.CAN-10-3604. PubMed: 21363922.
8. Dick JE, (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807. doi:10.1182/blood-2008-08-077941. PubMed: 19064739.
9. Eyler CE, Rich JN, (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26: 2839-2845. doi:10.1200/JCO.2007.15.1829. PubMed: 18539962.
10. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679. doi:10.1093/jnci/djn123. PubMed: 18445819.
11. Li Q-Q, Xu J-D, Wang W-J, Cao X-X, Chen Q, et al. (2009) Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15: 2657-2665. doi:10.1158/1078-0432.CCR-08-2372. PubMed: 19336515.
12. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106: 13820-13825. doi:10.1073/pnas.0905718106. PubMed: 19666588.
13. Sauvageau M, Sauvageau G, (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7: 299-313. doi:10.1016/j.stem.2010.08.002. PubMed: 20804967.
14. Siddique HR, Saleem M, (2012) Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 30: 372-378. doi:10.1002/stem.1035. PubMed: 22252887.
15. Cao L, Bombard J, Cintron K, Sheedy J, Weetall ML, et al. (2011) BMI1 as a novel target for drug discovery in cancer. J Cell Biochem 112: 2729-2741. doi:10.1002/jcb.23234. PubMed: 21678481.
16. Pirrotta V, (1998) Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 93: 333-336. doi:10.1016/S0092-8674(00)81162-9. PubMed: 9590168.
17. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM, (1991) Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 65: 753-763. doi:10.1016/0092-8674(91)90383-A. PubMed: 1904009.
18. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Guidon H, et al. (1991) Identification of cooperating oncogenes in Eμ- myc transgenic mice by provirus tagging. Cell 65: 737-752. doi:10.1016/0092-8674(91)90382-9. PubMed: 1904008.
19. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, et al. (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84: 1372-1376. doi:10.1054/bjoc.2001.1791. PubMed: 11355949.
20. Sawa M, Yamamoto K, Yokozawa T, Kiyoi H, Hishida A, et al. (2005) BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 82: 42-47. doi:10.1532/IJH97.05013. PubMed: 16105758.
21. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, et al. (2006) Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66: 6225-6232. doi:10.1158/0008-5472.CAN-06-0094. PubMed: 16778197.
22. Fan L, Xu C, Wang C, Tao J, Ho C, et al. (2012) Bmi1 is required for hepatic progenitor cell expansion and liver tumor development. PLOS ONE 7: e46472. doi:10.1371/journal.pone.0046472. PubMed: 23029524.
23. Michael LE, Westerman BA, Ermilov AN, Wang AQ, Ferris J, et al. (2008) Bmi1 Is Required for Hedgehog Pathway-Driven Medulloblastoma Expansion. Neoplasia 10: 1343-U1328. PubMed: 19048113.
24. Proctor E, Waghray M, Lee CJ, Heidt DG, Yalamanchili M, et al. (2013) Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLOS ONE 8: e55820. doi:10.1371/journal.pone.0055820. PubMed: 23437065.
25. Smith KS, Chanda SK, Lingbeek M, Ross DT, Botstein D, et al. (2003) Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol Cell 12: 393-400. doi:10.1016/S1097-2765(03)00277-6. PubMed: 14536079.
26. Song LB, Li J, Liao WT, Feng Y, Yu CP, et al. (2009) The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 119: 3626-3636. doi:10.1172/JCI39374. PubMed: 19884659.
27. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, et al. (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13: 317-323. doi:10.1038/ncb2173. PubMed: 21336307.
28. Zheng G, Peng F, Ding R, Yu Y, Ouyang Y, et al. (2010) Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis. J Cancer Res Clin Oncol 136: 1477-1488. doi:10.1007/s00432-010-0805-z. PubMed: 20700687.
29. Zhang W, Feng M, Zheng G, Chen Y, Wang X, et al. (2012) Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 417: 679-685. doi:10.1016/j.bbrc.2011.11.142. PubMed: 22166209.
30. Croce CM, Calin GA, (2005) miRNAs, cancer, and stem cell division. Cell 122: 6-7. doi:10.1016/j.cell.2005.06.036. PubMed: 16009126.
31. Sarkar FH, Li Y, Wang Z, Kong D, Ali S, (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Update 13: 57-66. doi:10.1016/j.drup.2010.02.001. PubMed: 20236855.
32. Blower PE, Chung J-H, Verducci JS, Lin S, Park J-K, et al. (2008) MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7: 1-9. doi:10.1186/1476-4598-7-1. PubMed: 18187804.
33. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377: 114-119. doi:10.1016/j.bbrc.2008.09.086. PubMed: 18834855.
34. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, et al. (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15: 5060-5072. doi:10.1158/1078-0432.CCR-08-2245. PubMed: 19671845.
35. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138: 592-603. doi:10.1016/j.cell.2009.07.011. PubMed: 19665978.
36. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601. doi:10.1038/ncb1722. PubMed: 18376396.
37. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ, (2007) Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 67: 7972-7976. doi:10.1158/0008-5472.CAN-07-1058. PubMed: 17804704.
38. Lerner M, Haneklaus M, Harada M, Grandér D, (2012) MiR-200c regulates Noxa expression and sensitivity to proteasomal inhibitors. PLoS One 7: pp. e36490.
39. Zhang Z, Zhang B, Li W, Fu L, Fu L, et al. (2011) Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes & Cancer 2: 782-791.
40. Abella V, Valladares M, Rodriguez T, Haz M, Blanco M, et al. (2012) miR-203 Regulates Cell Proliferation through Its Influence on Hakai Expression. PLOS ONE 7: e52568. doi:10.1371/journal.pone.0052568. PubMed: 23285092.
41. Li Y, Yuan Y, Tao K, Wang X, Xiao Q, et al. (2013) Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate. PLOS ONE 8: e61858. doi:10.1371/journal.pone.0061858. PubMed: 23613955.
42. Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, et al. (2012) Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene 32: 1-11. PubMed: 22907436.
43. Zhang Z, Zhang B, Li W, Fu L, Fu L, et al. (2011) Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes and Cancer,2(8):: 782-791. PubMed: 22393463.